- Call or text: +1 (808) 261-4476
- Mon-Fri (8:30am - 4:30pm) Lunch Break 12:30pm-1:30pm
- [email protected]
Edit Content
Conditions | Indications | Study Name | Treatment/MOA | NIH Website | Who Qualifies |
---|---|---|---|---|---|
Alzheimer’s Memory | MCI, Mild AD | Brainshuttle AD | IV RO7126209 (Trontinemab) | More info to come | MMSE > 22 |
Alzheimer’s Memory | MCI, Mild AD | ASCENT | SQ PRX012 – Next Generation Anti Amyloid (Must be willing to travel to partner Amyloid PET facility in LA) | Ascent Trial Info | MMSE >18 |
Alzheimer’s Memory | MCI, Mild Mod AD | PRESENCE | PO LY3154207(Mevidalen) D1 Receptors FIRST Hawaii Alzheimer's Trial Eligibility Verified with only Plasma P-Tau levels. No PET or CSF required! | NCT06538116 | MMSE 13-24 |
Alzheimer’s Memory | MCI, Mild Mod AD | PO CVL-231 (Emraclidine) M4 Receptors | NCT05644977 | MMSE 8-26 | |
Alzheimer’s Memory | AD, Agitation | PO NMRA-323511 V1a Rceptor | NCT06546995 | MMSE 5-24 | |
Parkinson’s | Early PD | LUMA | PO BIIB1222 - LRRK2 - DMT | NCT05348785 | PD within 2 years |
Parkinson’s | PD with Motor Flucations | PO Lu AF28996 – D1 D2 Agonist | NCT04291859 | > 1.5 hr OFF | |
Epilepsy | Focal Seizure | RISE 2 | PO BHV-7000 VG Potassium channel | NCT06132893 | > 4 seizures/month |
Epilepsy | Focal Seizure | X-TOLE2 | PO XEN1101 Novel Potassium channel | NCT05614063 | > 4 seizures/month |
Epilepsy | Primary Generalized | X-TOLE3 | PO XEN1101 Novel Potassium channel | NCT05667142 | 3 PGTC in 8 weeks |
Abortive | Focal or Generalized | STARS | Inhaled EP0162 Staccato Alprazolam | NCT05077904 | Seizures |
MS Neuroimmunology | RRMS | IV ABP 692 (More information to come) | |||
Neuromuscular | CIDP | IV HyQvia (More information to come) | |||
Neuromuscular | Myasthenia Gravis (Generalized) | PO LNP023 (Iptacopan) | NCT06517758 | MGFA Class II-IV | |
Neuromuscular | Spasticity | DIRECTION | IM Dysport Abobotulinumtoxin A | NCT04936542 | Spasticity > 3 mths |
Pain Migraine | PIONEER | PO LAHV/LAHW/Lasmiditan | NCT04396236 | Migraine > 6 mths | |
Rare Neuro Diseases | Huntington’s Chorea | DIMENSION | PO SAGE-718- NMDA PAM | NCT05107128 | CAG Mutation > 40U |
Rare Neuro Diseases | Dentatorubral-Pallidoluysian Atrophy | CYPRESS | Intrathecal ASO Therapy | ||
Psychiatric Neuro | Post Partum Dépression | RECONNECT | SQ RE 104 | NCT06342310 | DSM5 PostPD |
Principal Investigator, Clinical Research Center Hawaii Pacific Neuroscience Clinical Professor, Dept. of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research University of Hawai`i John Burns School of Medicine
Neurology
Neuroscience Chair
Director, Memory Disorders Center, Comprehensive Epilepsy Center, Neuro COVID Clinic, Center for Neuromodulation, Hawaii Pacific Neuroscience
Principal Investigator, Clinical Research Center, BRITL (Brain Research, Innovation & Translation Labs) BCI (Brain Computer Interface) & Brain Mapping Lab
Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai`i John A. Burns School of Medicine